Fasting insulin: the metabolic marker your standard panel might miss

Glucose can look fine while insulin is quietly climbing for a decade.

TL;DR

• Fasting insulin reveals the work your pancreas is doing to keep glucose normal — work that fasting glucose alone cannot see.
• A rising fasting insulin can show insulin resistance years before fasting glucose or A1C move out of range.
• The test is not on most standard panels and usually has to be requested. The number is most useful in context with glucose, A1C, and triglycerides.

What it is

Fasting insulin is a blood test that measures how much insulin (in plain English: the hormone the pancreas releases to move sugar out of the bloodstream and into cells) is in circulation after an overnight fast. It is reported in microunits per milliliter. The reference range most labs use is roughly 2 to 20 microunits per milliliter (Reaven, Diabetes, 1988).

How it works

Picture a thermostat set to 70 degrees. If the room gets cold, the heater works harder to keep it at 70. From the outside, the room temperature looks fine. Inside, the heater is straining. Fasting insulin is the equivalent of checking the heater — not just the thermometer. Your pancreas can pump out more and more insulin to keep glucose normal, sometimes for years, before the system breaks and glucose finally rises.

Who asks about it

People usually ask about fasting insulin after reading about insulin resistance or seeing the term in a longevity-oriented health resource. The question often follows a normal fasting glucose result that did not match how someone was actually feeling — fatigued after meals, gaining weight despite the same diet, or carrying more abdominal fat.

What the published research says

Roughly 1 in 3 US adults has prediabetes by current CDC estimates, and most do not know it (CDC National Diabetes Statistics Report). Fasting insulin and the related HOMA-IR calculation (homeostatic model assessment of insulin resistance) catch many of these cases earlier than glucose alone. The original work pointing to insulin resistance as a unifying metabolic problem dates back to Reaven’s 1988 Banting Lecture (Reaven, 1988).

What to know before considering it

Fasting insulin is a directional marker, not a diagnosis. It is most useful alongside fasting glucose, A1C, triglycerides, and HDL. Some medications (steroids, certain antipsychotics) shift insulin and should be flagged for the clinician interpreting the result. Lab assays vary; staying with the same lab over time helps trend the number meaningfully.

The Halftime POV

A normal glucose with rising insulin is not “fine” — it is an early warning. Asking your clinician to add fasting insulin to your next panel is a five-second request that can change the conversation by a decade.

Related reading:

• A1C and fasting glucose: the two metabolic baselines
• Biomarkers commonly tracked during peptide protocols
• The baseline blood panel: what to test before any peptide protocol

FAQ

Q: What is a normal fasting insulin level? A: Most reference ranges list 2 to 20 microunits per milliliter as “normal.” Functional medicine and metabolic-health clinicians often target the lower end — under 10, sometimes under 6 — because higher fasting insulin can signal early insulin resistance even when fasting glucose looks fine.

Q: Why is fasting insulin important? A: Fasting glucose can stay normal for years while the pancreas works harder and harder to keep it there. Fasting insulin reveals that hidden work. A rising fasting insulin is one of the earliest signs of insulin resistance — earlier than glucose, earlier than A1C.

Q: Why is fasting insulin not on most standard panels? A: Standard metabolic panels were built around fasting glucose, which is cheap and well-validated for diagnosing diabetes. Fasting insulin is more expensive and historically less standardized across labs. Many clinicians now order it specifically for metabolic-risk evaluation.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Reaven GM. Banting Lecture: Role of insulin resistance in human disease. Diabetes, 1988.
• CDC. National Diabetes Statistics Report.